Despite the fact that the incidence of obesity amongst children is rising fast, the impact of this on drug pharmacokinetics (PK) in children is largely unknown. Consequently this vulnerable patient population remains deprived from evidence-based drug treatment. Performing pediatric drug research in special pediatric populations remains extremely challenging. Pigs are propagated as innovative juvenile animal model for reliable prediction of PK in children, also by regulator agencies. In this project we will develop a juvenile piglet model to assess the impact of body composition changes on drug PK (cefazolin and paracetamol) in piglets and children. Changes in renal function, hepatic metabolism and tissue penetration in piglets will be mapped. Comparison of collected data will allow to assess the suitability of the obese piglet model for studying drug PK in children. This contributes to provide a solution to the negligence of specific pediatric patient populations in drug development.